Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Final OS Shows Survival Benefit in TNBC

What happened

Sichuan Kelun-Biotech reported final overall survival results from its Phase III OptiTROP-Breast01 trial. Sacituzumab tirumotecan showed a statistically significant survival benefit versus physician's choice chemotherapy in previously treated TNBC, with no new safety signals at 29.4 months.

Confirmed

Global impact / market context

A sustained survival benefit reduces doubt about the drug's effectiveness, which supports doctor confidence, uptake in approved uses and reimbursement cases. That can lift China revenue tied to two reimbursed indications, while partner Merck holds rights outside Greater China.

Analyst inference

The result reinforces the drug's competitive profile among TROP2 ADCs, a class of targeted cancer medicines. Investors may weigh later catalysts, such as first-line regulatory wins or approvals outside China from Merck's Phase III programs, against the already-approved later-line use.

Analyst inference

What to watch

1. National reimbursement inclusion covers two indications, which means public insurance listing that improves patient access and supports potential China revenue in breast cancer and NSCLC. Confirmed
2. Regulatory wins for first-line settings would expand the patient pool beyond previously treated disease, potentially increasing revenue and strengthening the case for wider reimbursement. Analyst inference
3. Approvals outside China from Merck's Phase III programs, given Merck holds ex-Greater China rights, could accelerate global uptake and value realization for the asset. Analyst inference

Evidence

• Original source link unavailable